# Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

> **NCT03694002** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 21 (actual)

## Conditions studied

- Locally Advanced Thymic Carcinoma
- Metastatic Thymic Carcinoma
- Recurrent Thymic Carcinoma
- Unresectable Thymic Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT03694002
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-03-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694002, "Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03694002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*